49 related articles for article (PubMed ID: 31393129)
1. PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein.
Holmstock N; Gonzalez FJ; Baes M; Annaert P; Augustijns P
Mol Pharm; 2013 Mar; 10(3):1056-62. PubMed ID: 23360470
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, molecular modeling, in vitro and in vivo biological evaluation of potent anthranilamide derivatives as dual P-glycoprotein and CYP3A4 inhibitors.
Said AM; Mansour YE; Soliman RR; Islam R; Fatahala SS
Eur J Med Chem; 2024 Jul; 273():116492. PubMed ID: 38762918
[TBL] [Abstract][Full Text] [Related]
3. Generation of tetracycline-controllable CYP3A4-expressing Caco-2 cells by the piggyBac transposon system.
Ichikawa M; Akamine H; Murata M; Ito S; Takayama K; Mizuguchi H
Sci Rep; 2021 Jun; 11(1):11670. PubMed ID: 34083621
[TBL] [Abstract][Full Text] [Related]
4. The arachidonic acid metabolite 11β-ProstaglandinF2α controls intestinal epithelial healing: deficiency in patients with Crohn's disease.
Coquenlorge S; Van Landeghem L; Jaulin J; Cenac N; Vergnolle N; Duchalais E; Neunlist M; Rolli-Derkinderen M
Sci Rep; 2016 May; 6():25203. PubMed ID: 27140063
[TBL] [Abstract][Full Text] [Related]
5. Lipidomic profiling in Crohn's disease: abnormalities in phosphatidylinositols, with preservation of ceramide, phosphatidylcholine and phosphatidylserine composition.
Sewell GW; Hannun YA; Han X; Koster G; Bielawski J; Goss V; Smith PJ; Rahman FZ; Vega R; Bloom SL; Walker AP; Postle AD; Segal AW
Int J Biochem Cell Biol; 2012 Nov; 44(11):1839-46. PubMed ID: 22728312
[TBL] [Abstract][Full Text] [Related]
6. The development of a functional human small intestinal epithelium model for drug absorption.
Kwon O; Jung KB; Lee KR; Son YS; Lee H; Kim JJ; Kim K; Lee S; Song YK; Jung J; Park K; Kim DS; Son MJ; Lee MO; Han TS; Cho HS; Oh SJ; Chung H; Kim SH; Chung KS; Kim J; Jung CR; Son MY
Sci Adv; 2021 Jun; 7(23):. PubMed ID: 34078609
[TBL] [Abstract][Full Text] [Related]
7. Reversal of abnormal collagen production in Crohn's disease intestinal biopsies treated with regenerating agents.
Alexakis C; Caruelle JP; Sezeur A; Cosnes J; Gendre JP; Mosnier H; Beaugerie L; Gallot D; Malafosse M; Barritault D; Kern P
Gut; 2004 Jan; 53(1):85-90. PubMed ID: 14684581
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticulate Drug Delivery Strategies to Address Intestinal Cytochrome P450 CYP3A4 Metabolism towards Personalized Medicine.
Zhang RX; Dong K; Wang Z; Miao R; Lu W; Wu XY
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452222
[TBL] [Abstract][Full Text] [Related]
9. Modulation of expression/function of intestinal P-glycoprotein under disease states.
Murakami T; Bodor E; Bodor N
Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):59-78. PubMed ID: 31821048
[No Abstract] [Full Text] [Related]
10. Drug-disease interaction: Clinical consequences of inflammation on drugs action and disposition.
Abdallah YEH; Chahal S; Jamali F; Mahmoud SH
J Pharm Pharm Sci; 2023; 26():11137. PubMed ID: 36942294
[TBL] [Abstract][Full Text] [Related]
11. Assessment of potential drug-drug interactions among outpatients in a tertiary care hospital: focusing on the role of P-glycoprotein and CYP3A4 (retrospective observational study).
Patel KA; Bhatt MH; Hirani RV; Patel VA; Patel VN; Shah GB; Chorawala MR
Heliyon; 2022 Nov; 8(11):e11278. PubMed ID: 36387483
[TBL] [Abstract][Full Text] [Related]
12. The Role of CYP3A in Health and Disease.
Klyushova LS; Perepechaeva ML; Grishanova AY
Biomedicines; 2022 Oct; 10(11):. PubMed ID: 36359206
[TBL] [Abstract][Full Text] [Related]
13. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs.
Alrubia S; Mao J; Chen Y; Barber J; Rostami-Hodjegan A
Clin Pharmacokinet; 2022 Oct; 61(10):1365-1392. PubMed ID: 36056298
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of using glucosylceramide synthase and cytochrome P450 family 1 subfamily A1 expression levels for patients with triple-negative breast cancer following neoadjuvant chemotherapy.
Liu J; Wang S; Wang C; Kong X; Sun P
Exp Ther Med; 2021 Mar; 21(3):247. PubMed ID: 33603855
[TBL] [Abstract][Full Text] [Related]
15. Parameterization of Microsomal and Cytosolic Scaling Factors: Methodological and Biological Considerations for Scalar Derivation and Validation.
Doerksen MJ; Jones RS; Coughtrie MWH; Collier AC
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):173-183. PubMed ID: 33340340
[TBL] [Abstract][Full Text] [Related]
16. Effect of Crohn's Disease on Villous Length and CYP3A4 Expression in the Pediatric Small Intestine.
Vyhlidal CA; Chapron BD; Ahmed A; Singh V; Casini R; Shakhnovich V
Clin Transl Sci; 2021 Mar; 14(2):729-736. PubMed ID: 33278326
[TBL] [Abstract][Full Text] [Related]
17. Crohn's Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression.
Wilson A; Urquhart BL; Ponich T; Chande N; Gregor JC; Beaton M; Kim RB
Mol Pharm; 2019 Sep; 16(9):4059-4064. PubMed ID: 31393129
[TBL] [Abstract][Full Text] [Related]
18. CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease.
Wilson A; Tirona RG; Kim RB
Inflamm Bowel Dis; 2017 May; 23(5):804-813. PubMed ID: 28301431
[TBL] [Abstract][Full Text] [Related]
19. Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease.
Fakhoury M; Lecordier J; Medard Y; Peuchmaur M; Jacqz-Agrain E
Inflamm Bowel Dis; 2006 Aug; 12(8):745-9. PubMed ID: 16917230
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
